During the last few years, remarkable progress has been made in gene and cell therapy. Positive proof-of-principle results have been obtained for several diseases, such as adrenoleukodystrophy, hemophilia IX, β-thalassemia, malignant glioblastoma, leukemia and other types of cancer. Thus, it is expected that several new gene therapy products will enter the clinical arena in the not-so-distant future. In cell therapy, iPS cell technology has opened huge possibilities for cell therapy and regenerative medicine. There are still significant challenges in gene and cell therapy before these new approaches can enter main stream medicine. Significant safety issues have been reported in some trials and the need for better vectors, delivery techniques and treatment genes are widely recognized. With years of experience in providing high-quality products and services in the field of biopharmaceuticals for customers all over the world, scientists in Creative Biolabs will be more focused on developing first class product and technology to meet the need of stem cell therapy development.